Evidence map›Paper›PMID 27793123›Full record

ArticleBMC cancer2016

Invasive myoepithelial carcinoma ex pleomorphic adenoma of the major salivary gland: two case reports.

Takahiro Wakasaki, Marie Kubota, Yutaka Nakashima, Eri Tomonobe, Takenao Mihara, Junichi Fukushima

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Carcinoma Ex Pleomorphic Adenoma of the Maxillary Sinus: Report of Two Cases.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025
    Article
  3. Molecular imaging and radionuclide therapy · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Takahiro WakasakiDepartment of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan. hayatenn@gmail.com.
Marie KubotaDepartment of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan.
Yutaka NakashimaDepartment of Pathology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan.
Eri TomonobeDepartment of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan.
Takenao MiharaDepartment of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan.
Junichi FukushimaDepartment of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Miniami-ku, Fukuoka, 815-8555, Japan.
Japanese Red Cross Fukuoka Hospital · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyoepithelial carcinoma (MEC) is a rare salivary gland tumor. Its long-term prognosis remains unknown because of the paucity of reported cases with long-term follow-up. Although some case series exist, the clinical features of MEC vary considerably depending on the site of origin. Therefore, accumulation of these rare cases is important. CASE PRESENTATION: Case 1: An 89-year-old man presented with a 10-year history of a mass originating from the right parotid gland and involving the neck. The mass grew rapidly for 3 months, reaching approximately 8 cm. There was no facial paralysis. MEC ex pleomorphic adenoma (PA) was suspected. Superficial parotid gland resection was performed in 2013; the tumor grade was pT3N0M0, and the resection margins were free of carcinoma. Because of several high-risk factors for metastasis (i.e., invasive carcinoma ex PA, high MIB1 index, and mutant p53 protein positivity), radiotherapy and chemotherapy were recommended as adjuvant therapy. Although the patient refused adjuvant therapy, he was recurrence-free at 36 months after surgery. Case 2: A 54-year-old woman presented with a >10-year history of a right submandibular mass, which grew rapidly for 1 year, reaching approximately 6 cm. Preoperative diagnosis was PA of the right submandibular gland. Submandibular gland resection was performed in 2013. Pathological analysis revealed invasive MEC ex PA, pT3N0M0; in addition, the carcinoma portion had an extra capsule and had invaded the platysma muscle close to the margin. An MIB1 index of 40 % and mutant p53 protein positivity indicated a high risk for metastasis. Additional resection and right neck dissection revealed no residual carcinoma. The patient refused adjuvant chemotherapy. One year after surgery, metastasis to the right pulmonary hilar node and both lungs were detected. Chemotherapy prevented recurrent growth of the lesion and extended survival. The patient was alive with cancer 30 months after the first surgery.

conclusionsHigh expression of the Ki67 labeling index might reflect prognosis of these cases. Chemotherapy for distant metastasis was effective, as expected. Further accumulation of cases and long follow-up data are needed to elucidate the pathophysiology and prognosis of MEC ex PA.

Indexed as

Adenoma, PleomorphicAged, 80 and overBiomarkers, TumorBiopsyCombined Modality TherapyFemaleHumansImmunohistochemistryMaleMiddle AgedMultimodal ImagingMyoepitheliomaNeoplasm InvasivenessNeoplasm StagingPrognosisRisk FactorsBiomarkers, TumorCase reportEx pleomorphic adenomaKi67 labeling indexMajor salivary glandMalignant myoepitheliomaMyoepithelial carcinoma

Identifiers

PMID27793123
PMCPMC5084397
OpenAlexW2540823204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.